Thomas Hielscher

List of Publications by Year
in descending order

193 papers	**14,189** citations	38660 **50** h-index	21474 **114** g-index
196 all docs	**196** docs citations	**196** times ranked	**18320** citing authors

#	Article	IF	Citations
1	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 2012, 482, 226-231.	13.7	2,129
2	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 2012, 22, 425-437.	7.7	1,551
3	Medulloblastoma Comprises Four Distinct Molecular Variants. Journal of Clinical Oncology, 2011, 29, 1408-1414.	0.8	1,131
4	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncology, The, 2017, 18, 682-694.	5.1	586
5	Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma. Cancer Cell, 2011, 20, 143-157.	7.7	494
6	The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation. Cell, 2013, 153, 1064-1079.	13.5	348
7	Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma. Journal of Clinical Oncology, 2010, 28, 1606-1610.	0.8	329
8	Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood, 2012, 119, 940-948.	0.6	327
9	TERT Promoter Mutations and Risk of Recurrence in Meningioma. Journal of the National Cancer Institute, 2016, 108, djv377.	3.0	283
10	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	5.1	274
11	Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene, 2013, 32, 1173-1182.	2.6	252
12	Adult Medulloblastoma Comprises Three Major Molecular Variants. Journal of Clinical Oncology, 2011, 29, 2717-2723.	0.8	215
13	Molecular Staging of Intracranial Ependymoma in Children and Adults. Journal of Clinical Oncology, 2010, 28, 3182-3190.	0.8	210
14	Cell competition is a tumour suppressor mechanism in the thymus. Nature, 2014, 509, 465-470.	13.7	209
15	Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load. Journal of Clinical Oncology, 2013, 31, 4325-4332.	0.8	200
16	Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathologica, 2011, 122, 231-240.	3.9	195
17	Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica, 2011, 96, 87-95.	1.7	188
18	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathologica, 2013, 125, 373-384.	3.9	169

#	Article	IF	Citations
19	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	0.8	160
20	Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica, 2010, 95, 1150-1157.	1.7	154
21	mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 409-414.	3.3	152
22	Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia, 2018, 32, 383-390.	3.3	152
23	<i>FSTL5</i> Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma. Journal of Clinical Oncology, 2011, 29, 3852-3861.	0.8	143
24	Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathologica, 2010, 120, 253-260.	3.9	129
25	Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer Journal, 2017, 7, e599-e599.	2.8	124
26	Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia, 2015, 29, 1721-1729.	3.3	123
27	Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica, 2012, 97, 1757-1760.	1.7	116
28	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathologica, 2020, 140, 409-413.	3.9	116
29	Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathologica, 2018, 135, 955-963.	3.9	109
30	HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas. Journal of Clinical Investigation, 2013, 123, 2488-2501.	3.9	109
31	Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia, 2014, 28, 1902-1908.	3.3	105
32	Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood, 2009, 113, 4331-4340.	0.6	97
33	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. Journal of Clinical Oncology, 2021, 39, 3839-3852.	0.8	93
34	MicroRNAâ€30câ€2â€3p negatively regulates NFâ€Î°B signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer. Molecular Oncology, 2015, 9, 1106-1119.	2.1	82
35	Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-Oncology, 2013, 15, 1017-1026.	0.6	78
36	A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathologica, 2011, 122, 637-650.	3.9	77

#	Article	IF	Citations
37	High‐Dimensional Cox Models: The Choice of Penalty as Part of the Model Building Process. Biometrical Journal, 2010, 52, 50-69.	0.6	69
38	Integrated molecular characterization of <i><scp>IDH</scp></i>‐mutant glioblastomas. Neuropathology and Applied Neurobiology, 2019, 45, 108-118.	1.8	68
39	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathologica, 2012, 123, 515-527.	3.9	66
40	Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance. Leukemia, 2014, 28, 174-178.	3.3	66
41	Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma. Carcinogenesis, 2011, 32, 1467-1473.	1.3	64
42	A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR. Epigenetics, 2012, 7, 772-780.	1.3	64
43	Toward an integrated map of genetic interactions in cancer cells. Molecular Systems Biology, 2018, 14, e7656.	3.2	64
44	Role of LIM and SH3 Protein 1 (LASP1) in the Metastatic Dissemination of Medulloblastoma. Cancer Research, 2010, 70, 8003-8014.	0.4	62
45	Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica, 2015, 100, 964-969.	1.7	62
46	Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Annals of Hematology, 2011, 90, 429-439.	0.8	60
47	Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation. Annals of Oncology, 2012, 23, 1795-1802.	0.6	60
48	MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathologica, 2012, 123, 529-538.	3.9	60
49	Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. Blood Cancer Journal, 2021, 11, 1.	2.8	57
50	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. Clinical Cancer Research, 2019, 25, 1851-1866.	3.2	55
51	Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer, 2011, 117, 2136-2144.	2.0	54
52	<i>GRHL1</i> Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by MYCN and HDAC3. Cancer Research, 2014, 74, 2604-2616.	0.4	54
53	Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Journal of Neurosurgery, 2009, 111, 211-218.	0.9	51
54	The insulin-like growth factor binding proteins 3 and 7 are associated with colorectal cancer and liver metastasis. Cancer Biology and Therapy, 2011, 12, 69-79.	1.5	51

#	ARTICLE	IF	CITATIONS
55	Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival. Cell Death and Disease, 2017, 8, e2635-e2635.	2.7	48
56	Kinome-wide shRNA Screen Identifies the Receptor Tyrosine Kinase AXL as a Key Regulator for Mesenchymal Glioblastoma Stem-like Cells. Stem Cell Reports, 2015, 4, 899-913.	2.3	47
57	Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia, 2020, 34, 1853-1865.	3.3	47
58	Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget, 2016, 7, 44322-44329.	0.8	47
59	A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. Haematologica, 2015, 100, 818-825.	1.7	45
60	Asymmetric distribution of TLR3 leads to a polarized immune response in human intestinal epithelial cells. Nature Microbiology, 2020, 5, 181-191.	5.9	45
61	Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. Haematologica, 2021, 106, 2754-2758.	1.7	45
62	Gene Expression Profiling in Multiple Myelomaâ€"Reporting of Entities, Risk, and Targets in Clinical Routine. Clinical Cancer Research, 2011, 17, 7240-7247.	3.2	43
63	Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. Oncotarget, 2017, 8, 11460-11479.	0.8	43
64	Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. Clinical Cancer Research, 2019, 25, 253-265.	3.2	42
65	Nestin Expression Identifies Ependymoma Patients with Poor Outcome. Brain Pathology, 2012, 22, 848-860.	2.1	40
66	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. Leukemia, 2019, 33, 696-709.	3.3	40
67	The renal microenvironment modifies dendritic cell phenotype. Kidney International, 2016, 89, 82-94.	2.6	38
68	Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica, 2016, 101, e116-e119.	1.7	37
69	Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia, 2021, 35, 1134-1144.	3.3	36
70	Fully Automated Pulmonary Lobar Segmentation: Influence of Different Prototype Software Programs onto Quantitative Evaluation of Chronic Obstructive Lung Disease. PLoS ONE, 2016, 11, e0151498.	1.1	35
71	The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis. Tumor Biology, 2016, 37, 2461-2471.	0.8	35
72	Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Advances, 2018, 2, 2607-2618.	2.5	33

#	ARTICLE	IF	CITATIONS
73	Sequential biphasic changes in claudin1 and claudin4 expression are correlated to colorectal cancer progression and liver metastasis. Journal of Cellular and Molecular Medicine, 2012, 16, 260-272.	1.6	30
74	Fibroblast growth factor receptor 4 gene (*FGFR4*) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. International Journal of Cancer, 2012, 131, E586-91.	2.3	29
75	Targeting atypical protein kinase C iota reduces viability in glioblastoma stemâ€like cells *via* a notch signaling mechanism. International Journal of Cancer, 2016, 139, 1776-1787.	2.3	29
76	Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients. Epigenetics, 2016, 11, 61-73.	1.3	29
77	Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study. European Radiology, 2016, 26, 1404-1411.	2.3	28
78	Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. American Journal of Hematology, 2016, 91, E473-E477.	2.0	27
79	Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology. European Radiology, 2016, 26, 3939-3948.	2.3	27
80	Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial. Bone Marrow Transplantation, 2017, 52, 1194-1198.	1.3	27
81	Prognostic impact of genetic alterations and methylation classes in meningioma. Brain Pathology, 2022, 32, e12970.	2.1	27
82	Risk Factors for Local Recurrence of Large, Flat Colorectal Polyps after Endoscopic Mucosal Resection. Digestion, 2016, 93, 311-317.	1.2	26
83	Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma. Leukemia, 2020, 34, 1192-1196.	3.3	26
84	Patients With Cancer of Unknown Primary. Deutsches Ärzteblatt International, 2014, 111, 481-7.	0.6	25
85	Increased microcirculation detected by dynamic contrastâ€enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma. British Journal of Haematology, 2016, 174, 127-135.	1.2	25
86	Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. Blood Advances, 2018, 2, 1-9.	2.5	25
87	Germline Allele-Specific Expression of DAPK1 in Chronic Lymphocytic Leukemia. PLoS ONE, 2013, 8, e55261.	1.1	24
88	Inhibition of hepatocellular carcinoma growth by blockade of glycosphingolipid synthesis. Oncotarget, 2017, 8, 109201-109216.	0.8	23
89	Oncolytic effects of parvovirus Hâ€1 in medulloblastoma are associated with repression of master regulators of early neurogenesis. International Journal of Cancer, 2014, 134, 703-716.	2.3	22
90	Prognostic relevance of miRNA-155 methylation in anaplastic glioma. Oncotarget, 2016, 7, 82028-82045.	0.8	21

#	ARTICLE	IF	CITATIONS
91	T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells. British Journal of Cancer, 2020, 122, 1023-1036.	2.9	20
92	Appearance of monoclonal plasma cell diseases in whole‐body magnetic resonance imaging and correlation with parameters of disease activity. International Journal of Cancer, 2014, 135, 2380-2386.	2.3	19
93	Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e480.	3.1	19
94	Epigenetic Silencing of DKK3 in Medulloblastoma. International Journal of Molecular Sciences, 2013, 14, 7492-7505.	1.8	18
95	Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients. Journal of Neurology, 2017, 264, 341-349.	1.8	18
96	Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation. Haematologica, 2018, 103, 336-343.	1.7	18
97	Micronucleus formation in human cancer cells is biased by chromosome size. Genes Chromosomes and Cancer, 2019, 58, 392-395.	1.5	17
98	Risk factors associated with progressive lacunar strokes and benefit from dual antiplatelet therapy. European Journal of Neurology, 2020, 27, 817-824.	1.7	17
99	Pathogenetic pathways leading to glioblastoma multiforme: association between gene expressions and resistance to erlotinib. Anticancer Research, 2008, 28, 3729-32.	0.5	17
100	A Robust Alternative to the Schemper-Henderson Estimator of Prediction Error. Biometrics, 2011, 67, 524-535.	0.8	16
101	Caspase-8 modulates physiological and pathological angiogenesis during retina development. Journal of Clinical Investigation, 2019, 129, 5092-5107.	3.9	16
102	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. Oncotarget, 2016, 7, 59029-59048.	0.8	16
103	Combining Deep Learning and Radiomics for Automated, Objective, Comprehensive Bone Marrow Characterization From Whole-Body MRI. Investigative Radiology, 2022, 57, 752-763.	3.5	16
104	Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients. Oncotarget, 2018, 9, 25254-25264.	0.8	15
105	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. Brain Pathology, 2016, 26, 506-516.	2.1	14
106	Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Haematologica, 2016, 101, e485-e487.	1.7	14
107	Longitudinal fluorescence *in situ* hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. Haematologica, 2017, 102, 1432-1438.	1.7	14
108	Hyperosmolarity impedes the cross-priming competence of dendritic cells in a TRIF-dependent manner. Scientific Reports, 2017, 7, 311.	1.6	14

#	Article	IF	Citations
109	A PRDX1–p38α heterodimer amplifies MET–driven invasion of <i>IDH</i>–wildtype and <i>IDH</i>–mutant gliomas. International Journal of Cancer, 2018, 143, 1176-1187.	2.3	14
110	Telomere length, arsenic exposure and risk of basal cell carcinoma of skin. Carcinogenesis, 2019, 40, 715-723.	1.3	14
111	Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. International Journal of Cancer, 2020, 146, 3053-3064.	2.3	14
112	Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma. Blood, 2018, 132, 254-254.	0.6	14
113	Meta-Analysis of Randomized Controlled Trials on Yoga, Psychosocial, and Mindfulness-Based Interventions for Cancer-Related Fatigue: What Intervention Characteristics Are Related to Higher Efficacy?. Cancers, 2022, 14, 2016.	1.7	14
114	A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in <i>BRAF</i>-Driven Pediatric Low-Grade Glioma Cells. Molecular Cancer Therapeutics, 2020, 19, 1736-1750.	1.9	13
115	Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib. Anticancer Research, 2008, 28, 3725-8.	0.5	13
116	Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma. Child's Nervous System, 2013, 29, 1253-1262.	0.6	12
117	cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma. Journal of Neuro-Oncology, 2020, 146, 9-23.	1.4	12
118	The Glycome of Normal and Malignant Plasma Cells. PLoS ONE, 2013, 8, e83719.	1.1	12
119	Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL. Cancer Biology and Therapy, 2014, 15, 1185-1197.	1.5	11
120	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. Acta Neuropathologica, 2018, 136, 975-978.	3.9	11
121	Susceptibility–weighted imaging in malignant melanoma brain metastasis. Journal of Magnetic Resonance Imaging, 2019, 50, 1251-1259.	1.9	11
122	Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse. Blood, 2018, 132, 253-253.	0.6	11
123	Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders - a Study of the International Myeloma Working Group. Blood, 2016, 128, 4468-4468.	0.6	11
124	ADCK2 Knockdown Affects the Migration of Melanoma Cells via MYL6. Cancers, 2022, 14, 1071.	1.7	11
125	Metastasis-Related Processes Show Various Degrees of Activation in Different Stages of Pancreatic Cancer Rat Liver Metastasis. Oncology Research and Treatment, 2014, 37, 464-470.	0.8	10
126	Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative. Digestion, 2016, 94, 129-137.	1.2	10

#	Article	IF	Citations
127	Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance. Leukemia, 2018, 32, 2717-2719.	3.3	10
128	Bortezomib-Based Induction Therapy Followed by Autologous Stem Cell Transplantation and Maintenance Therapy with Bortezomib Improves Outcome In Myeloma Patients with Gain 1q21 and t(4;14) - a Subgroup Analysis of the HOVON-65/GMMG-HD4 Trial. Blood, 2010, 116, 305-305.	0.6	10
129	How to evaluate agreement between quantitative measurements. Radiotherapy and Oncology, 2019, 141, 321-326.	0.3	8
130	Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns. Cancers, 2021, 13, 961.	1.7	8
131	Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial. Journal of Hematology and Oncology, 2019, 12, 65.	6.9	7
132	Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma. Blood Cancer Journal, 2019, 9, 71.	2.8	7
133	Marginal variable screening for survival endpoints. Biometrical Journal, 2020, 62, 610-626.	0.6	7
134	Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Prognostic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma Patients. Biology of Blood and Marrow Transplantation, 2020, 26, 1280-1287.	2.0	7
135	Comparison of single-scanner single-protocol quantitative ADC measurements to ADC ratios to detect clinically significant prostate cancer. European Journal of Radiology, 2021, 136, 109538.	1.2	7
136	NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm. Genes Chromosomes and Cancer, 2010, 49, 333-341.	1.5	6
137	SMC3 protein levels impact on karyotype and outcome in acute myeloid leukemia. Leukemia, 2019, 33, 795-799.	3.3	6
138	Conditional Alox12b Knockout: Degradation of the Corneocyte Lipid Envelope in a Mouse Model of Autosomal Recessive Congenital Ichthyoses. Journal of Investigative Dermatology, 2020, 140, 249-253.e6.	0.3	6
139	Comparison of Peripheral Zone and Central Gland Volume in Patients Undergoing Intensity-Modulated Radiotherapy. Journal of Computer Assisted Tomography, 2010, 34, 739-745.	0.5	5
140	Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. Journal of Neuro-Oncology, 2016, 129, 533-539.	1.4	5
141	Invitation letters increase participation in colorectal cancer screening â€" results from an observational study. Zeitschrift Fur Gastroenterologie, 2017, 55, 1307-1312.	0.2	5
142	Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. Leukemia, 2019, 33, 258-261.	3.3	5
143	Clinical outcome of patients with follicular lymphoma and bulky disease after Rituximabâ€"CHOP immunochemotherapy with and without consolidating radiotherapy. European Journal of Haematology, 2010, 85, 11-19.	1.1	4
144	Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy. Leukemia and Lymphoma, 2020, 61, 27-36.	0.6	4

#	Article	IF	Citations
145	Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma. Blood, 2010, 116, 2396-2396.	0.6	4
146	The Proportion of Clonal Plasma Cells In the Bone Marrow Analyzed by FISH Rather Than Single Chromosomal Abnormalities Predict Progression From Smoldering to Symptomatic Multiple Myeloma. Blood, 2010, 116, 2950-2950.	0.6	4
147	Multiple behavioral factors are associated with occurrence of large, flat colorectal polyps. International Journal of Colorectal Disease, 2017, 32, 575-582.	1.0	3
148	Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up. Blood, 2019, 134, 3308-3308.	0.6	3
149	GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance â€" Final Analysis On Induction Therapy. Blood, 2013, 122, 3369-3369.	0.6	3
150	Asymptomatic Multiple Myeloma - Background of Progression, Evolution, and Prognosis. Blood, 2016, 128, 235-235.	0.6	3
151	Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation. International Journal of Hematology, 2013, 97, 765-772.	0.7	2
152	Transcriptional profiling of dendritic cells matured in different osmolarities. Genomics Data, 2016, 7, 64-66.	1.3	2
153	The effect of gender-specific invitation letters on utilization ofÂcolorectal cancer screening. Zeitschrift Fur Gastroenterologie, 2019, 57, 1051-1058.	0.2	2
154	Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma. Blood, 2015, 126, 4233-4233.	0.6	2
155	Over 30% of Smoldering Myeloma Patients Have Tumor Cell Bone Marrow Infiltration Patterns Similar to Multiple Myeloma: A Large (n=544) Clinical Study Using Whole-Body MRI.. Blood, 2012, 120, 2911-2911.	0.6	2
156	Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more costâ€effective and safer treatment of advanced follicular lymphoma. American Journal of Hematology, 2012, 87, E68-71.	2.0	1
157	GTF2I Mutation in Thymomas: Independence From Racial-Ethnic Backgrounds. An Indian/German Comparative Study. Pathology and Oncology Research, 2021, 27, 1609858.	0.9	1
158	Quantitative Integrative Prediction of Survival Probability in Multiple Myeloma Using Molecular and Clinical Prognostic Factors in 657 Patients Treated with Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation. Blood, 2018, 132, 403-403.	0.6	1
159	Profiling of Oncogenic Signaling in Multiple Myeloma â€" Association with Biology, Disease Progression and Prognosis. Blood, 2018, 132, 3206-3206.	0.6	1
160	The Chromosomal Abnormalities Del(17p), t(4;14), and +1q21 Predict Progression From Smoldering to Symptomatic Multiple Myeloma. Blood, 2012, 120, 1806-1806.	0.6	1
161	Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma â€" Subgroup Analysis from the GMMG-MM5 Trial. Blood, 2014, 124, 3475-3475.	0.6	1
162	Signaling Pathway Profiling in Multiple Myeloma. Blood, 2014, 124, 644-644.	0.6	1

#	Article	IF	Citations
163	Longitudinal Fluorescence in Situ Hybridization at Primary Diagnosis and Relapse Reveals Clonal Evolution after Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2016, 128, 4415-4415.	0.6	1
164	A Gene Expression Based Proliferation Index as Independent Prognostic Factor in Multiple Myeloma.. Blood, 2008, 112, 1667-1667.	0.6	1
165	High-Dose Therapy with Peripheral Blood Stem Cell Transplantation for Patients with Multiple Myeloma: Prognostic Impact of Chromosomal Aberrations and Correlation with the ISS-Score. Blood, 2008, 112, 2708-2708.	0.6	1
166	Appearance of Monoclonal Plasma Cell Diseases in Whole Body MRI in 544 Patients and Correlation with Parameters of Disease Activity. Blood, 2012, 120, 4966-4966.	0.6	1
167	Asymptomatic Multiple Myeloma â€" Molecular Background of Progression and Prognosis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e9-e10.	0.2	0
168	Normalization of serum free light chains during therapy in the MM5 trial predicts prolonged progression free survival and overall survival. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e208.	0.2	0
169	Impact of cytogenetics at relapse on prognosis and benefit from salvage autologous stem cell transplantation in the GMMG phase III trial ReLApsE. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e286-e287.	0.2	0
170	Impact of Gene Expression Profiling on Diagnosis and Prognostication in Cytogenetically Normal AML.. Blood, 2008, 112, 1487-1487.	0.6	0
171	Clinical Outcome of Patients with Follicular Lymphoma and Bulky Disease After Rituximab-CHOP Immunochemotherapy with and without Consolidating Radiotherapy.. Blood, 2009, 114, 2722-2722.	0.6	0
172	A Clinically Usable Gene Expression Report for Risk Assessment and Identification of Possible Therapeutic Targets in Multiple Myeloma.. Blood, 2009, 114, 1829-1829.	0.6	0
173	Achievement of CR and nCR Before and After First High-Dose Therapy Followed by Autologous Stem Cell Transplantation Is a Major Marker for Long-Term Survival in Multiple Myeloma Patients.. Blood, 2009, 114, 3400-3400.	0.6	0
174	How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Combined with 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Lymphoma (HD2000-Trial).. Blood, 2009, 114, 2687-2687.	0.6	0
175	Cytogenetic Abnormalities and Appearance of Multiple Myeloma in Whole Body-MRI.. Blood, 2009, 114, 4868-4868.	0.6	0
176	Gene Expression Analysis of Independent Data Sets Identifies HBG1 to Be Associated with Outcome in Cytogenetically Normal AML.. Blood, 2009, 114, 2613-2613.	0.6	0
177	Correlation of Serological and MRI-Based Treatment Response to Systemic Chemotherapy In 100 Patients with Multiple Myeloma. Blood, 2010, 116, 2977-2977.	0.6	0
178	Metascoring and Gene Expression Profiling in Clinical Routine in Multiple Myeloma,. Blood, 2011, 118, 3940-3940.	0.6	0
179	Prognostic Significance of the Number of Focal Lesions in Whole Body Magnetic Resonance Imaging Before and After Autologous Stem Cell Transplantation. Blood, 2011, 118, 1812-1812.	0.6	0
180	Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial. Blood, 2011, 118, 332-332.	0.6	0

#	Article	IF	Citations
181	Impact Of Response Duration and Maintenance Therapy After Autologous Stem Cell Transplantation On Long-Term Survival In Multiple Myeloma Patients. Blood, 2013, 122, 3183-3183.	0.6	0
182	Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial. Blood, 2013, 122, 1897-1897.	0.6	0
183	Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG. Blood, 2014, 124, 4777-4777.	0.6	0
184	Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4. Blood, 2015, 126, 3187-3187.	0.6	0
185	Clinical Impact of KMT2C and SPRY4 Expression Levels in Intensively Treated Younger Adult Acute Myeloid Leukemia Patients. Blood, 2016, 128, 1663-1663.	0.6	0
186	Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal. Blood, 2018, 132, 4485-4485.	0.6	0
187	Modeling of the Epigenome of the Cell-of-Origin Identifies Cancer-Specific DNA Methylation Patterns in CLL. Blood, 2018, 132, 3885-3885.	0.6	0
188	Cohesin Subunit SMC3 Levels Impact on Karyotype and Outcome in Acute Myeloid Leukemia. Blood, 2018, 132, 2786-2786.	0.6	0
189	P-177: Predictive factors for severe infections and early death during novel agent-based induction therapy in newly diagnosed, transplant-eligible myeloma: a multicohort analysis from phase III trials. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S133-S134.	0.2	0
190	P-138: Frequent magnetic resonance imaging partially reduces the development of end organ damage in patients with smoldering myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S110-S111.	0.2	0
191	P-188: Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S140-S141.	0.2	0
192	Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network. Blood, 2021, 138, 3792-3792.	0.6	0
193	P-017: Repeatability and reproducibility of apparent diffusion coefficient measurements of bone marrow in magnetic resonance imaging of multiple myeloma patients. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S48-S49.	0.2	0